Persistence of the immune response induced by BCG vaccination by Weir, Rosemary E et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Persistence of the immune response induced by BCG vaccination
Rosemary E Weir, Patricia Gorak-Stolinska*, Sian Floyd, Maeve K Lalor, 
Sally Stenson, Keith Branson, Rose Blitz, Anne Ben-Smith, Paul EM Fine and 
Hazel M Dockrell
Address: London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
Email: Rosemary E Weir - drw@gn.apc.org; Patricia Gorak-Stolinska* - patricia.gorak-stolinska@lshtm.ac.uk; 
Sian Floyd - sian.floyd@lshtm.ac.uk; Maeve K Lalor - maeve.lalor@lshtm.ac.uk; Sally Stenson - sallystenson@yahoo.co.uk; 
Keith Branson - keith.branson@lshtm.ac.uk; Rose Blitz - rose.blitz@lshtm.ac.uk; Anne Ben-Smith - annebensmith@googlemail.com; 
Paul EM Fine - paul.fine@lshtm.ac.uk; Hazel M Dockrell - hazel.dockrell@lshtm.ac.uk
* Corresponding author    
Abstract
Background: Although BCG vaccination is recommended in most countries of the world, little is known
of the persistence of BCG-induced immune responses. As novel TB vaccines may be given to boost the
immunity induced by neonatal BCG vaccination, evidence concerning the persistence of the BCG vaccine-
induced response would help inform decisions about when such boosting would be most effective.
Methods: A randomised control study of UK adolescents was carried out to investigate persistence of
BCG immune responses. Adolescents were tested for interferon-gamma (IFN-γ) response to
Mycobacterium tuberculosis purified protein derivative (M.tb PPD) in a whole blood assay before, 3 months,
12 months (n = 148) and 3 years (n = 19) after receiving teenage BCG vaccination or 14 years after
receiving infant BCG vaccination (n = 16).
Results: A gradual reduction in magnitude of response was evident from 3 months to 1 year and from 1
year to 3 years following teenage vaccination, but responses 3 years after vaccination were still on average
6 times higher than before vaccination among vaccinees. Some individuals (11/86; 13%) failed to make a
detectable antigen-specific response three months after vaccination, or lost the response after 1 (11/86;
13%) or 3 (3/19; 16%) years. IFN-γ response to Ag85 was measured in a subgroup of adolescents and
appeared to be better maintained with no decline from 3 to 12 months. A smaller group of adolescents
were tested 14 years after receiving infant BCG vaccination and 13/16 (81%) made a detectable IFN-γ
response to M.tb PPD 14 years after infant vaccination as compared to 6/16 (38%) matched unvaccinated
controls (p = 0.012); teenagers vaccinated in infancy were 19 times more likely to make an IFN-γ response
of > 500 pg/ml than unvaccinated teenagers.
Conclusion:  BCG vaccination in infancy and adolescence induces immunological memory to
mycobacterial antigens that is still present and measurable for at least 14 years in the majority of vaccinees,
although the magnitude of the peripheral blood response wanes from 3 months to 12 months and from
12 months to 3 years post vaccination. The data presented here suggest that because of such waning in
the response there may be scope for boosting anti-tuberculous immunity in BCG vaccinated children
anytime from 3 months post-vaccination. This supports the prime boost strategies being employed for
some new TB vaccines currently under development.
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Background
BCG vaccination is given to young infants in most coun-
tries of the world, and the UK has recently changed its vac-
cination policy to recommend giving BCG primarily to
infants in high risk communities [1]. The emphasis upon
neonatal vaccination raises the question of the longevity
of the protective immune response induced by BCG vacci-
nation. There are few data on the protective effect of infant
vaccination on later incidence of pulmonary TB. A review
of ten separate studies of vaccine recipients of all ages
indicated protection waned after 10 – 15 years [2] but a
study in Brazil has shown protection for at least 20 years
[3] and a recent analysis of data from North American
Indians indicated protection could last for up to 60 years
[4]. Though several studies have examined the persistence
and waning of BCG-induced tuberculin reactivity [5] there
are very few data on the long term persistence of in vitro
measures of the immune response to BCG.
Recent studies have measured the in vitro interferon-
gamma (IFN-γ) response to mycobacterial antigens
(including M.tb PPD) in diluted whole blood cultures to
monitor the immune response to BCG vaccination in ado-
lescents/young adults in the UK and Malawi [6]. UK teen-
agers, in whom BCG has been shown to provide 50–80%
protection against pulmonary TB [7], showed little pre-
existing T-cell response to M.tb PPD prior to vaccination,
but a clear BCG-attributable increase one year after vacci-
nation. The data presented here is part of a larger data set
from an ongoing study comparing the immune responses
to BCG vaccination in adolescents and infants in the UK
and Malawi, with the purpose of determining correlates of
protective efficacy for use in TB vaccine trials. In the UK,
BCG vaccination has a protective efficacy of 50–80% [7]
while in Malawi it is believed to provide little additional
protection to adolescent or adult recipients [8] while there
is strong evidence to support the assumption that it is
highly efficacious when given to neonates [9]. We have
previously determined, in UK and Malawian adolescents,
that an increase in BCG attributable M.tb PPD specific
IFN-γ response one year post vaccination is associated
with the protective efficacy of the BCG vaccine [6]. We
now present data to examine more closely the mainte-
nance of the immune response to BCG vaccination
among UK teenagers, who were vaccinated either as
infants or as adolescents.
Methods
Recruitment and study design
This work was carried out within the routine schools BCG
programme in Redbridge and Waltham Forest Health
Authority (RWFHA) in south-east England, as previously
described [10,11]. Approval for this research was given by
the RWFHA Local Research Ethics Committee and the Eth-
ics Committee of the London School of Hygiene & Tropi-
cal Medicine. Sample collection was carried out between
December 2002 and July 2004.
Early maintenance of response to BCG vaccination among teenagers
IFN-γ responses in whole blood cultures were measured
among 14–15 year olds prior to, and at 3 months and one
year after vaccination with Danish strain 1331 BCG. Chil-
dren were recruited via a letter distributed to parents/
guardians, which explained the purpose of the study and
contained a written consent form and questionnaire
which recorded ethnic group and travel history (time
spent outside the UK) [10]. Children with a record of and/
or scar evidence of previous BCG vaccination were
excluded from the study. All other recruits were given a
Heaf skin test using M.tb tuberculin PPD, BP (100,000 U/
ml, Evans Medical Limited, Leatherhead, UK), following
UK standard procedures [12] at recruitment and 12
months later. Children with a Heaf grade ≥ 2 at recruit-
ment were ineligible for BCG vaccination, and those with
a Heaf grade ≥ 3 were referred for active investigation for
tuberculosis, following standard procedures [12]. The
remaining children were randomly allocated to receive
BCG vaccination immediately, or to have it delayed by a
year. Participants were recalled for follow-up testing three
and twelve months after vaccination. Individuals with
Heaf grade < 2, 12 months after recruitment, whose BCG
vaccination had been delayed were offered BCG vaccina-
tion at the 12 month follow-up.
Maintenance of the response 3 years after teenage vaccination
17–18 year olds, vaccinated with Glaxo 1077 BCG (the
vaccine in use prior to autumn 2002) at the baseline time-
point of our previous study, and tested by whole blood
assay at baseline and one year after vaccination [13], were
invited by letter to give a third blood sample, three years
after vaccination. Three schools were approached, all of
which were participating in the other arms of the study.
All participants and their guardians gave their informed
consent, and a travel history since the previous blood test
was taken.
Maintenance of the response 14 years after infant vaccination
IFN-γ responses were measured among 12–14 year olds,
14 years after infant BCG vaccination. Children with a his-
tory of BCG vaccination in the first year of life were invited
to participate; details of age at vaccination and place or
country of vaccination were collected by parental ques-
tionnaire and examination of child health records. Unvac-
cinated children from the main vaccination study acted as
controls.
Whole blood assay and IFN-γ ELISA
Blood collection, whole blood assays and IFN-γ ELISA
were carried out as previously described[10]. IFN-γ was
measured in 6 day supernatants by ELISA [13]. The limitsBMC Infectious Diseases 2008, 8:9 http://www.biomedcentral.com/1471-2334/8/9
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of detection of the assay were 31 – 2000 pg/ml. Test anti-
gens were Mycobacteria tuberculosis (M.tb) PPD (SSI; Batch
RT48, lot 191(17–18 year olds study, first and second
blood assays) and Batch RT49, lots 204 and 206 (all other
assays)) at 5 µg/ml; and for the 14–15 year olds vaccina-
tion study, M.tb Antigen 85 A, B, C, purified native anti-
gen 10 µg/ml (Dr J. Belisle, Colorado State University,
Fort Collins, USA; through the NIH, NIAID funded pro-
gramme continued under the HHSN266200400091c "TB
Vaccine Testing & Research Materials" contract; lot
01.rv.2.3.21.10Ag85). Controls were PHA (Difco Labora-
tories/Becton Dickinson, Oxford, UK, 5 µg/ml); streptoki-
nase-streptodornase (SK/SD, Varidase, Wyeth
Laboratories, Maidenhead, Berks, UK, 250 U/ml) (17–18
year olds study only); and medium alone (RPMI) as the
negative control.
Statistical analysis
Data were double entered and analysed using STATA 8.1
as previously described [14]. In brief, all values below the
limit of detection of the IFN-γ assay < 31 pg/ml were set at
15 pg/ml (the mid point between 0 and 30). Negative
control values were subtracted from all results. A positive
IFN-γ response was defined as > 62 pg/ml, twice the limit
of detection of the assay. The threshold aims to reduce the
inclusion of false positive responses and the frequency
distribution data from the prevaccination responses
among these teenagers indicates that the response thresh-
old is appropriate as previously described [10,13]. To
determine if there was a significant vaccine related change
in response between the pre and post vaccination time
points we compared how many times higher (or lower)
the vaccine induced change was than the change in the
control group (fold change). Analysis presented here are
restricted further to include only individuals who had
data at each time point. Ethnic group was categorised as
Caucasian, Black, Asian, mixed race, and other. Differ-
ences among ethnic groups were further assessed restrict-
ing the analysis to children who had not travelled outside
the UK.
Results
Early maintenance of response to BCG vaccination among 
teenagers
Two hundred and thirteen teenagers aged 12–14 years
were recruited into the study, of whom 189 were eligible
for vaccination. Of these, 148 provided a blood sample at
baseline and 3 and 12 months after vaccination, and had
a Heaf skin test at baseline and 12 months after vaccina-
tion. Analysis was restricted to these 148: 78/148 (53%)
were male; 123/148 (83%) were Caucasian, the remain-
der were 'Black' (n = 14), 'Asian' (n = 3), 'mixed race' (n =
2) or 'other' (n = 6). The majority (119/148) had never
travelled to tropical areas. Eighty-six (58%) received BCG
vaccination at baseline.
Prevalence and magnitude of IFN-γ responses to M.tb PPD
and Ag85, and to RPMI and PHA at the different time
points are shown in Table 1. Responses to medium alone
were generally negative (≤ 8% showing a positive
response), and to PHA very high, among both vaccinees
and controls, at all three time points.
Figure 1 shows IFN-γ responses to M.tb PPD at the differ-
ent time points among controls and vaccinees. Consistent
with our previous results [10,13] there were few respond-
ers (IFNγ response > 62 pg/ml) to M.tb PPD prior to BCG
vaccination, and a marked increase in response at 3 and
12 months after vaccination which is not seen in the con-
trol group. Figure 2 shows the frequency distributions of
changes in magnitude of IFN-γ response to M.tb PPD
between baseline and (a) 3 months and (b) 12 months
after BCG vaccination, with control data for comparison.
The average increases in vaccinees/controls were 12.4 -
fold (p < 0.001)(95% CI 7.7–19.7) and 7.5-fold (p <
0.001)(95% CI 4.5–12.3) at 3 and 12 months respec-
Table 1: Effect of BCG vaccination of UK teenagers on IFN-γ responses to mycobacterial and control antigens. n= 148 (control group n 
= 62, vaccine group n = 86) except Ag85 where n= 43 (baseline), 50 (3 months), 49 (12 months).
Time after vaccination
Baseline 3 months 12 months
Antigen Control Vaccinated Control Vaccinated Control Vaccinated
M.tb PPD % responders 23 19 31 87 19 74
Median pg/ml (IQ range) 0 (0–60) 0 (0–36) 0 (0–103) 488 (150–1178) 0 (0–46) 214 (57–822)
p value Vaccinated versus Control 0.5 < 0.001 < 0.001
M.tb Ag85 % responders 78 72 90 100 62 96
Median pg/ml (IQ range) 184 (61–721) 168 (45–426) 813 (221–1340) 1192 (865–2353) 112 (0–262) 808 (386–1865)
p value Vaccinated versus Control 0.67 0.09 0.002
RPMI % responders 5 7 8 6 3 6
Median pg/ml (IQ range) 15 (15) 15 (15) 15 (15) 15 (15) 15 (15) 15 (15)
PHA % responders 97 100 98 97 87 86
Median pg/ml (IQ range) 2940 (1432–3692) 3200 (2225–4700) 3807 (1496–4529) 3578 (2610–4092) 2578 (314–3357) 2797 (548–4202)
p value Vaccinated versus Control 0.09 0.76 0.85BMC Infectious Diseases 2008, 8:9 http://www.biomedcentral.com/1471-2334/8/9
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tively. The 12 month response was on average 0.6 times (p
= 0.02) (95% CI 0.4–0.9) that of the 3 month response.
The size of change in response to M.tb PPD at 12 months
was associated with that at 3 months after vaccination
(Spearman rank correlation, r = 0.6).
Responses to Ag85 were already highly prevalent among
UK teenagers before BCG vaccination (Table 1), which
makes the vaccine-induced response less straightforward
to interpret. A vaccine-induced effect was still evident,
with a mean 2.8-fold increase (p = 0.04)(95% CI 1.0–7.5)
in response at 3 months (Figure 2c) and 5.9-fold increase
(p = 0.002)(95% CI 2.0–17.8) at 12 months (Figure 2d).
The vaccine-induced response to Ag85 was better main-
tained at 12 months than that to M.tb PPD, with no evi-
dence that the effect of the vaccine waned between 3 and
12 months (p = 0.18). All vaccinated subjects were mak-
ing a response to Ag85 at three months, and 96% were
still responding at 12 months.
An increase in response was also seen among control sub-
jects at 3 months to Ag85 (Figure 2c) (p = 0.02). This was
not observed to M.tb PPD (Figure 2a) (p = 0.34). This
effect on the response to Ag85 was lost by 12 months (p =
0.27).
Maintenance of the response 3 years after teenage 
vaccination
Twenty 17–18 year old teenagers recruited into our earlier
study accepted the invitation for further participation. The
sample from one subject made no response to test anti-
gens or positive control at the Year 3 test, and was
excluded from analysis.
Figure 3 shows IFN-γ response to M.tb PPD in the teenag-
ers tested before, 1 and 3 years after, vaccination with
Glaxo 1077 BCG. The IFN-γ response to M.tb PPD for the
group (n = 19) rose on average 10.2 times (95% CI = 4.9–
21.4) from baseline to 1 year. This compares with a mean
increase of 9.2 -fold (95% CI 6.8 – 12.5) for the complete
group of 424 children vaccinated at the same time in our
first study [13]; and of 7.5 -fold (p < 0.001)(95% CI 4.5–
12.3) for the children in our second study as reported
above. The mean increase from baseline to 3 years was 6.2
times (p < 0.001) (95% CI = 3.3–11.6), consistent with
waning of responses between one and three years by a fac-
tor of 0.6 (p = 0.10).
IFN-γ responses to a non-mycobacterial antigen, SK/SD,
did not increase over the same time period (data not
shown); the size of change of IFN-γ response to M.tb PPD
was significantly higher (p < 0.001) than that to SK/SD
both 1 and 3 years after BCG vaccination, indicating that
this is a mycobacterial antigen specific effect.
There was a moderate correlation between the change in
response of an individual between baseline and 1 year
after vaccination, and between baseline and 3 years after
vaccination (Spearman Rank correlation r = 0.58). This
change is of the same order as observed 3 and 12 months
after vaccination, as reported above. This suggests that the
magnitude of the persistent response to vaccination can
be quite well predicted by the initial response to vaccina-
tion. However, three individuals (16%) who made a
response after 1 year made no detectable response after
three years. Of 6 individuals (31%) who were non or bor-
der line responders to M.tb PPD 1 year after vaccination,
4 were still unresponsive after 3 years, but 2 individuals
did make responses. Thus responses to mycobacterial
antigens can increase as well as decrease over this period.
Maintenance of the response 14 years after infant 
vaccination
Forty-three 12–14 year old teenagers with a history of
BCG vaccination within the first year of life were recruited.
Average time between vaccination and blood test was 14
years, ranging from 12 years 1 month to 14 years 7
months. A group of 212 children of similar age with no
history of previous BCG acted as controls. Figure 4 shows
IFN-γ responses to M.tb PPD among those who were vac-
cinated in infancy (Fig 4a) compared to unvaccinated
IFN-γ response to M.tb PPD at baseline, and at 3 and 12  months following BCG vaccination, among teenage unvacci- nated controls and vaccinees Figure 1
IFN-γ response to M.tb PPD at baseline, and at 3 and 
12 months following BCG vaccination, among teen-
age unvaccinated controls and vaccinees. Control sub-
jects n = 62, vaccinated subjects n = 86. Each box shows the 
median and 25th and 75th centiles. The "whiskers" show the 
minimum and maximum values other than outliers which are 
represented as dots above the "whiskers". Grey line repre-
sents threshold of positive IFN-γ response (> 62 pg/ml; twice 
the limit of detection of the assay (31 pg/ml) [13]).
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teenagers (Fig 4b). Of those vaccinated as infants, 32/43
(74 %) were responders (> 62 pg/ml), compared to 51/
212 (24 %) of those with no history of vaccination (p <
0.001).
Although this suggests that an appreciable proportion of
infant vaccinations lead to persistent IFN-γ responses to
mycobacterial antigens, it is likely that some of the infant
vaccinees may have been vaccinated for reasons (e.g. fam-
ily history of tuberculosis, immigrant ethnic group) which
could provide alternative reasons for positive IFN-γ
responses. Twenty four of 43 (56%) were Black or Asian,
and our questionnaire revealed that 28/43 (65 %) had vis-
ited the tropics, which we have shown to be associated
with higher sensitivity to mycobacterial antigens [10]. For
17/43, the BCG vaccination had been administered over-
seas or could not be confirmed as having been adminis-
tered in the UK. This group is also likely to have been
vaccinated with different strains of BCG.
Change in IFN-γ response to M.tb PPD and M.tb Antigen 85 three and twelve months after BCG vaccination Figure 2
Change in IFN-γ response to M.tb PPD and M.tb Antigen 85 three and twelve months after BCG vaccination. 
Bars represent proportion of the group showing a particular size of change between the timepoints indicated.
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IFN-γ responses to M.tb PPD in UK teenagers tested before,  one and three years after BCG vaccination Figure 3
IFN-γ responses to M.tb PPD in UK teenagers tested 
before, one and three years after BCG vaccination. 
Each triplet of linked points represents IFN-γ response of 
vaccinated individuals at baseline, one (Year 1) and three 
(Year 3) years after vaccination with Glaxo 1077 BCG.
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To clarify the effect of the infant BCG vaccination, the
groups were restricted in two ways. Firstly, the infant-vac-
cinated group was restricted to those who were Caucasian,
who had been vaccinated within the first year of life in the
UK, and had never travelled to the tropics (n = 6; Figure
4c). These were matched by school to children who were
Caucasian and had never travelled to the tropics (n = 94;
Figure 4d). Within these groups, 3 (50%) of the vacci-
nated children and 21 (22%) of the unvaccinated children
made an IFN-γ response to M.tb PPD of > 62 pg/ml (p =
0.15, Fisher's exact test); 2 (33%) and 1 (1%) respectively
made a response > 500 pg/ml (p = 0.01, Fisher's exact
test). Although a statistically significant difference is
apparent at the higher level of response, this restriction
provided only a very small group of infant-vaccinated
children. A further analysis was carried out, matching
infant-vaccinated with unvaccinated children by ethnic
group, time spent in tropics, geographical area (e.g. South
Asia, Caribbean, southern Africa) and where possible
exact country visited. Matching also by school was possi-
ble for the six infant-vaccinated Caucasian children who
had not travelled to tropical countries. This provided 16
matched pairs of vaccinated versus unvaccinated individ-
uals who had travelled to tropical countries (Figures 4e
and 4f), together with 6 infant-vaccinated Caucasian stu-
dents and 94 unvaccinated controls who had not travelled
to the tropics. Combining the two groups, and controlling
for travel to tropical countries, provided evidence of
higher IFN-γ responses among individuals who were
infant-vaccinated (odds ratio 5.2 (p = 0.004) [95% CI
1.5–18.3] of having a response > 62 pg/ml, and odds ratio
19.3 (p < 0.001) [95% CI 2.4–155.1], of having a
response > 500 pg/ml), compared to individuals who
were not.
Some of the Caucasian children who had not travelled to
the tropics were also tested with Ag85 (n = 33; unvacci-
nated n = 27, vaccinated n = 6). There was no difference
between the groups in their IFN-γ response (> 62 pg/ml)
to Ag85: 74% of the unvaccinated group and 83% of vac-
cinees made a response. Using a higher response thresh-
old (> 500 pg/ml), 22% of the unvaccinated group and
50% of the vaccinated group made a response. This indi-
cates a higher prevalence of high responses to Ag85
among vaccinees, but low power due to small group sizes
did not reveal a statistically significant difference between
the two groups.
Discussion
This study set out to determine the duration of the
immune response induced by BCG vaccination in teenag-
ers in the UK, up to 3 years after teenage vaccination or 14
years after infant vaccination. The immune response was
measured by IFN-γ response in diluted whole blood cul-
ture following 6 days stimulation with M.tb PPD, M.tb
Antigen 85, or an appropriate control.
Our results show the effect of infant vaccination in the UK
can persist for at least 14 years as measured by the in vitro
IFN-γ response to M.tb PPD. The magnitude of the meas-
ured response, while much higher than that of unvacci-
nated children, was likely to be lower than the initial
response to vaccination, as our study of teenagers showed
evidence of highest responses at 3 months after vaccina-
tion, with a reduction to 0.6 of the 3 month response by
12 months, and a further reduction to 0.6 of the 12 month
response at three years.
In addition to M.tb PPD, we measured responses to Ag85
isolated from M.tuberculosis. This antigen has homologues
in all known species of mycobacteria and has been identi-
fied as a prominent target of the immune response against
mycobacteria. It is currently a component of several new
tuberculosis vaccines[15]. We have evidence from a previ-
ous study that IFN-γ responses to M. bovis BCG Ag85 are
highly prevalent among UK teenagers before they receive
BCG vaccination (manuscript in preparation). A lack of
response to M.tb Ag85 in UK cord blood samples, with
increasing prevalence of response in blood from BCG-
Frequency distributions of IFN-γ responses to M.tb PPD  among 12–14-year olds in the UK, as a function of infant  BCG vaccination history, ethnic group and travel history Figure 4
Frequency distributions of IFN-γ responses to M.tb 
PPD among 12–14-year olds in the UK, as a function 
of infant BCG vaccination history, ethnic group and 
travel history. Bars represent proportion of each group 
making an IFN-γ response of particular magnitude.
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unvaccinated infants over the first year of life (manuscript
in preparation), also point to a common environmental
exposure to this antigen in the UK. In spite of this, a vac-
cine-induced increase in response to M.tb Ag85 was
observed in our vaccinees, though with a different kinetic
of response to that seen to M.tb PPD, the response was
maintained at 12 months at its 3 month level. This is
likely to follow an initial peak of response in the first
month following vaccination, as studies of vaccination of
adults from the UK with MVA-85A (and BCG) using ex
vivo ELISPOT to Ag85A peptides (and PPD) as the meas-
ure of response found a marked fall in response after this
initial period [15]. In animal model systems it has been
demonstrated that prior exposure to different environ-
mental mycobacteria can have an effect on the response to
subsequent BCG vaccination either blocking the prolifer-
ation of BCG [16] or masking the effect of the BCG by pro-
viding as much protection as the vaccine [17]. In the case
of Ag85, it may be that repeated environmental exposure
to a source of Ag85 maintains response to this antigen and
contributes to the persistence of the response to M.tb
PPD, of which Ag85 is a major component, so contribut-
ing neither to masking nor blocking but to persistence of
the response.
Teenagers who had received BCG vaccination in infancy
showed no difference in response to Ag85 compared to
unvaccinated teenagers at a low threshold of response (<
62 pg/ml), but there was a suggestion that infant BCG vac-
cination leads to more prevalent high (> 500 pg/ml)
responses to Ag85 14 years after vaccination (50% of vac-
cinated versus 22% unvaccinated), though it should be
emphasised this is based upon small numbers and not sta-
tistically significant. Larger group sizes would be needed
to see if a BCG-induced response to Ag85 persists over
many years. Exposure to an environmental species which
naturally sensitises individuals to Ag85 makes a persistent
vaccine effect more difficult to ascertain with increasing
age.
An additional finding from this study was that IFN-γ
responses to Ag85 were increased among control subjects
at 3 months but not at 12 months. As the same batch of
the Ag85 preparation was used at each time point this
could reflect some boosting effect by the tuberculin test.
Boosting effects have been documented when testing on
the day of TST reading or within one month post TST
though none using the same assay or at the same time
point as in our study [18]. Further human studies of this
effect would provide valuable insights.
A recent study has demonstrated that vaccine-induced T-
cell response to smallpox antigens can persist for as long
as 67 years, in the absence of environmental boosting
effects [19]. The authors concluded that this long term
memory was attributable mainly to the central memory T-
cell population; the effector memory population waned
much more rapidly although it could be restored by revac-
cination. The same study examined the IFN-γ response to
PPD, by ELISpot assay, among ten individuals aged 25–63
years, who had received BCG vaccination in childhood,
and found it to be maintained both in central and effector
memory compartments. The authors conjectured that
environmental mycobacterial exposure helped to main-
tain this response, but no unvaccinated controls were
included in the study. Our observed reduction in the mag-
nitude of the peripheral blood IFN-γ response could rep-
resent a contraction of the effector memory population
with a residual persistent central memory population. We
know that at least some individuals in this UK population
are exposed to environmental mycobacteria [10,13],
which may provide a low-level boosting effect and main-
tain a small peripheral memory T-cell population to
mount the observed IFN-γ response to mycobacterial anti-
gens. Although the unvaccinated control group of teenag-
ers in our study showed some prior sensitivity to M.tb
PPD, as expected [10], the children vaccinated in infancy
showed a greatly increased IFN-γ response to M.tb PPD as
compared to unvaccinated controls. It may be that envi-
ronmental exposure boosts pre-existing vaccine-induced
responses, as well as inducing a response per se in unvac-
cinated individuals.
BCG is the only currently available licensed vaccine
against TB, and is typically administered in infancy,
including now in the UK. With the worldwide resurgence
of TB, it is important to assess longevity of protection
afforded by BCG. Information about the induction and
maintenance of anti-mycobacterial immune mechanisms
by BCG is also relevant for new TB vaccines currently in
development [20] as several of these vaccines are designed
to act as a booster vaccination following BCG, and such
information may inform decisions about the best timing
for such boosting.
Conclusion
In conclusion, BCG vaccination of infants in the UK pro-
vokes a response in the majority of vaccinees which can
persist for at least 14 years, as measured by the IFN-γ
response to mycobacterial antigens of peripheral blood
cultures. The maintenance of memory T-cell IFN-γ
responses to Ag85 implies that BCG vaccination primes T-
cell responses that could be boosted by the new vaccines
incorporating Ag85A or Ag85B that are currently under
development or entering trials. However, recent studies in
Malawi show that, against an already high response to
mycobacterial antigens, BCG vaccination induces an
increased IFN-γ response to mycobacterial antigens that is
detectable at 3 months, but is much lower by 12 months
[21]. This may reflect a reduced ability of the MalawianBMC Infectious Diseases 2008, 8:9 http://www.biomedcentral.com/1471-2334/8/9
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group to generate new longer term central memory cells
due to high environmental mycobacterial exposure over-
stimulating an activated effector cell population. As the
majority of new cases of TB are in the tropics, and this is
where BCG has consistently failed to provide protection
against adult disease, it is important to better understand
these factors to arrive at a new vaccine which will succeed
where BCG has failed.
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